Results 1 to 10 of about 75,745 (278)

Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder [PDF]

Hematology Reports, 2011
We present the 16th reported case of Acute Lymphoblastic Leukemia (ALL) with involvement in the bladder. Our patient was a 22 yearold man with T-cell ALL with a mediastinal mass.
Alexander Pham, Amir Steinberg, Brian Kwok, Angela Lopez, Stephen Lim, Michael Lill   +5 more
doaj   +8 more sources

Precursor NK cell lymphoblastic leukemia/lymphoma - report of a case with literature review [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2014
Precursor Natural Killer cell lymphoblastic leukemia/lymphoma is a rare entity defined clearly by WHO (2008 WHO classification). However, the pathobiology of this subset of neoplasms is not clearly defined.
Sonal Jain, Rajeev Kumar, Abhishek Purohit, Hara Prasad Pati   +3 more
doaj   +5 more sources

Signal Pathway in Precursor B-Cell Lymphoblastic Leukemia/Lymphoma [PDF]

, 2017
Stat5, c-myc, Hipk2, Fiz1, and ZFP521 to lymphomagenesis precursor B-cell lymphoblastic lymphoma/leukemia have been previously identified as a putative gene involved in the induction of B-cell lymphomagenesis.
Takuya Hiratsuka, Tatsuaki Tsuruyama
core   +7 more sources

Precursor B-Cell Acute Lymphoblastic Leukemia/Lymphoma with L3 Morphology, Philadelphia Chromosome, MYC Gene Translocation, and Coexpression of TdT and Surface Light Chains: A Case Report [PDF]

Case Reports in Pathology, 2013
Acute lymphoblastic leukemia is predominantly found in children. It is a neoplasm of precursor cells or lymphoblasts committed to either a B- or T-cell lineage.
Alicia C. Hirzel, Aaron Cotrell, Robert Gasparini, Vathany Sriganeshan   +3 more
doaj   +6 more sources

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma [PDF]

Biomarker Research, 2022
AbstractPatients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expression in almost all T-cell malignancies.
Hai-ping Dai, Wei Cui, Qing-ya Cui, Wen-juan Zhu, Hui-min Meng, Min-qing Zhu, Xia-ming Zhu, Lin Yang, De-pei Wu, Xiao-wen Tang   +9 more
openaire   +4 more sources

Drug-Induced Cauda Equina Syndrome in an 8-Year-Old Boy With Acute Lymphoblastic Leukemia: An Uncommon Case Report. [PDF]

Clin Case Rep
ABSTRACT Intrathecal methotrexate can cause cauda equina syndrome in pediatric ALL patients, as demonstrated in this rare case of an 8‐year‐old boy. Symptoms included progressive limb weakness and urinary retention. Early recognition, prompt discontinuation of the offending agent, and multidisciplinary management are crucial.
Babaee M, Javadzadeh M, Hazeghi A.
europepmc   +2 more sources

Inhibiting H3K27 Demethylases Downregulates CREB‐CREBBP, Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia [PDF]

Cancer Med
This study investigates the effect of epigenetic regulator GSK‐J4 in the downregulation of CREB and CREBBP in acute lymphoblastic leukemia (ALL) cell lines and relapsed patient samples, leading to apoptosis induction and cell cycle arrest. We propose H3K27 demethylase inhibition as a potential treatment strategy for patients with treatment‐resistant ...
Lazaro‐Navarro J, Alcon C, Dorel M, Alasfar L, Bastian L, Baldus C, Astrahantseff K, Yaspo M, Montero J, Eckert C.   +9 more
europepmc   +2 more sources

CBFA2T3::GLIS2‐positive acute leukemia with RAM and mixed T/megakaryocytic phenotype

eJHaem, 2023
Herein, we present a rare case of acute myeloid leukemia (AML) with CBFA2T3‐rearrangement and the expression of megakaryocytic and lymphoid markers, highlighting the need for a high suspicion index in differential diagnosis and applying adequate workup ...
Mahsa Khanlari, Lu Wang, Christine Y Bolen, Felipe Sebastian Bautista Otanez, Larissa V. Furtado, Laura Key, Lisa Irwin, Wei Wang, Jeffery M. Klco   +8 more
doaj   +1 more source

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

American Journal of Hematology, Volume 98, Issue 1, Page 159-165, January 2023., 2023
Donor stem cell product undergoes CD34 stem cell selection. CD34 positive stem cells are used for transplantation. Pathogen‐ and leukemia‐specific T‐cells are manufactured from CD34 negative fraction and infused prophylactically 21 days after transplant.
David J. Gottlieb, Gaurav Sutrave, Wei Jiang, Selmir Avdic, Janine A. Street, Renee Simms, Leighton E. Clancy, Vicki Antonenas, Brian S. Gloss, Caroline Bateman, David C. Bishop, Kenneth P. Micklethwaite, Emily Blyth   +12 more
wiley   +1 more source

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023
Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn   +4 more
wiley   +1 more source